Quarterly report (Form 10-Q)
Edwards Lifesciences 10-Q for Quarter ended Sep 30, 2026
Filing excerpt
The increase in the effective rate between the nine months ended September 30, 2026 and 2025 was primarily due to a $174.4 million valuation allowance recorded against certain deferred tax assets in the second and third quarters of 2026 as a result of enactment of California budget legislation on June 29, 2026, which, as noted below, permanently limits the utilization of most business tax credits, including carryovers of research and development tax credits